ALK-Abelló

Report Publication Announcement • Apr 30, 2013

Copenhagen, 2013-04-30 11:40 CEST (GLOBE NEWSWIRE) --

ALK releases its three-month interim report (Q1) 2013 on Friday, 3 May 2013,
before 9.00 a.m. (CET).

ALK will host a meeting for analysts and institutional investors that day at
2.00 p.m. (CET) at which Jens Bager, President and CEO, and Flemming Pedersen,
CFO, will review the financial results, the outlook and answer questions.
Following the presentation of the financial results, Henrik Jacobi, EVP R&D
will present ALK’s clinical development programme for the new immunotherapy
tablet for the treatment of allergic asthma and rhinitis caused by house dust
mites. Results from two European Phase III trials are expected later in 2013.
The meeting takes place at Nordea, Heerings Gaard, Overgaden neden Vandet 11,
0900 Copenhagen K, Denmark.

If you wish to participate in the meeting, please email events@nordea.com or
call tel. +45 33 33 25 38.

The meeting will also be audio cast. Participants in the audio cast are kindly
requested to call in before 1.55 p.m. (CET). Danish participants should call in
on tel. +45 70 26 50 40 or +45 70 27 90 09 and international participants
should call in on tel. +44 208 817 9301. The audio cast is available live on
our website www.alk-abello.com/investor, where the related presentation will be
available shortly before the meeting begins.

                             ALK-Abelló A/S


                               Jens Bager
                            President and CEO

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143